{
"info": {
"nct_id": "NCT01463631",
"official_title": "A Phase 1 Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer",
"inclusion_criteria": "* Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic for which available standard therapies have failed to provide clinical benefit for their disease\n* For Dose Escalation (Part A): cancer, either a solid tumor or a lymphoma\n* For Dose Confirmation (Part B): cancer, either a solid tumor or a lymphoma\n* Have the presence of measureable or non-measureable disease (Part A) or measureable disease (Part B) as defined by the Response Evaluation Criteria in Solid Tumors or the Revised Response Criteria for Malignant Lymphoma\n* Have adequate hematologic, hepatic and renal function\n* Have a performance status less than or equal to 2 on the Eastern Cooperative Oncology Group scale\n* Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, and immunotherapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents\n* Have an estimated life expectancy of greater than or equal to 12 weeks\n* Are able to swallow capsules\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Have an echocardiogram with clinically significant abnormalities\n* For Dose Escalation (Part A): Have central nervous system malignancy or metastasis\n* For Dose Confirmation (Part B): Have symptomatic central nervous system malignancy or metastasis\n* Have an acute leukemia\n* Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and stopped all therapy for that disease for a minimum of 3 years\n* Have received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic for which available standard therapies have failed to provide clinical benefit for their disease",
"criterions": [
{
"exact_snippets": "histological or cytological evidence of a diagnosis of cancer",
"criterion": "diagnosis of cancer",
"requirement": {
"requirement_type": "evidence",
"expected_value": [
"histological",
"cytological"
]
}
},
{
"exact_snippets": "cancer that is advanced and/or metastatic",
"criterion": "cancer stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"advanced",
"metastatic"
]
}
},
{
"exact_snippets": "available standard therapies have failed to provide clinical benefit",
"criterion": "response to standard therapies",
"requirement": {
"requirement_type": "response",
"expected_value": "failed to provide clinical benefit"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "histological or cytological evidence of a diagnosis of cancer",
"criterion": "diagnosis of cancer",
"requirement": {
"requirement_type": "evidence",
"expected_value": [
"histological",
"cytological"
]
}
},
{
"exact_snippets": "cancer that is advanced and/or metastatic",
"criterion": "cancer stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"advanced",
"metastatic"
]
}
}
]
},
{
"exact_snippets": "available standard therapies have failed to provide clinical benefit",
"criterion": "response to standard therapies",
"requirement": {
"requirement_type": "response",
"expected_value": "failed to provide clinical benefit"
}
}
]
}
},
{
"identified_line": {
"line": "* Have the presence of measureable or non-measureable disease (Part A) or measureable disease (Part B) as defined by the Response Evaluation Criteria in Solid Tumors or the Revised Response Criteria for Malignant Lymphoma",
"criterions": [
{
"exact_snippets": "presence of measureable or non-measureable disease (Part A)",
"criterion": "disease presence (Part A)",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "presence of measureable or non-measureable disease (Part A)",
"criterion": "disease presence (Part A)",
"requirement": {
"requirement_type": "measurability",
"expected_value": [
"measurable",
"non-measurable"
]
}
},
{
"exact_snippets": "measureable disease (Part B)",
"criterion": "disease presence (Part B)",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "measureable disease (Part B)",
"criterion": "disease presence (Part B)",
"requirement": {
"requirement_type": "measurability",
"expected_value": "measurable"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "presence of measureable or non-measureable disease (Part A)",
"criterion": "disease presence (Part A)",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "presence of measureable or non-measureable disease (Part A)",
"criterion": "disease presence (Part A)",
"requirement": {
"requirement_type": "measurability",
"expected_value": [
"measurable",
"non-measurable"
]
}
}
]
},
{
"exact_snippets": "as defined by the Response Evaluation Criteria in Solid Tumors or the Revised Response Criteria for Malignant Lymphoma",
"criterion": "definition criteria",
"requirement": {
"requirement_type": "definition",
"expected_value": "Response Evaluation Criteria in Solid Tumors or Revised Response Criteria for Malignant Lymphoma"
}
}
]
},
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "measureable disease (Part B)",
"criterion": "disease presence (Part B)",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "measureable disease (Part B)",
"criterion": "disease presence (Part B)",
"requirement": {
"requirement_type": "measurability",
"expected_value": "measurable"
}
}
]
},
{
"exact_snippets": "as defined by the Response Evaluation Criteria in Solid Tumors or the Revised Response Criteria for Malignant Lymphoma",
"criterion": "definition criteria",
"requirement": {
"requirement_type": "definition",
"expected_value": "Response Evaluation Criteria in Solid Tumors or Revised Response Criteria for Malignant Lymphoma"
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Have adequate hematologic, hepatic and renal function",
"criterions": [
{
"exact_snippets": "adequate hematologic ... function",
"criterion": "hematologic function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
},
{
"exact_snippets": "adequate ... hepatic ... function",
"criterion": "hepatic function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
},
{
"exact_snippets": "adequate ... renal function",
"criterion": "renal function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "adequate hematologic ... function",
"criterion": "hematologic function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
},
{
"exact_snippets": "adequate ... hepatic ... function",
"criterion": "hepatic function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
},
{
"exact_snippets": "adequate ... renal function",
"criterion": "renal function",
"requirement": {
"requirement_type": "adequacy",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Have a performance status less than or equal to 2 on the Eastern Cooperative Oncology Group scale",
"criterions": [
{
"exact_snippets": "performance status less than or equal to 2 on the Eastern Cooperative Oncology Group scale",
"criterion": "performance status",
"requirement": {
"requirement_type": "scale",
"expected_value": "Eastern Cooperative Oncology Group"
}
},
{
"exact_snippets": "performance status less than or equal to 2 on the Eastern Cooperative Oncology Group scale",
"criterion": "performance status",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "performance status less than or equal to 2 on the Eastern Cooperative Oncology Group scale",
"criterion": "performance status",
"requirement": {
"requirement_type": "scale",
"expected_value": "Eastern Cooperative Oncology Group"
}
},
{
"exact_snippets": "performance status less than or equal to 2 on the Eastern Cooperative Oncology Group scale",
"criterion": "performance status",
"requirement": {
"requirement_type": "value",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, and immunotherapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents",
"criterions": [
{
"exact_snippets": "Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, and immunotherapy) for at least 21 days for myelosuppressive agents",
"criterion": "discontinuation of myelosuppressive cancer therapies",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "days"
}
}
},
{
"exact_snippets": "Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, and immunotherapy) ... 14 days for nonmyelosuppressive agents",
"criterion": "discontinuation of nonmyelosuppressive cancer therapies",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 14,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, and immunotherapy) for at least 21 days for myelosuppressive agents",
"criterion": "discontinuation of myelosuppressive cancer therapies",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "days"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, and immunotherapy) ... 14 days for nonmyelosuppressive agents",
"criterion": "discontinuation of nonmyelosuppressive cancer therapies",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 14,
"unit": "days"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Have an estimated life expectancy of greater than or equal to 12 weeks",
"criterions": [
{
"exact_snippets": "estimated life expectancy of greater than or equal to 12 weeks",
"criterion": "life expectancy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "estimated life expectancy of greater than or equal to 12 weeks",
"criterion": "life expectancy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Are able to swallow capsules",
"criterions": [
{
"exact_snippets": "able to swallow capsules",
"criterion": "ability to swallow capsules",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "able to swallow capsules",
"criterion": "ability to swallow capsules",
"requirement": {
"requirement_type": "ability",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Have an echocardiogram with clinically significant abnormalities",
"criterions": [
{
"exact_snippets": "echocardiogram with clinically significant abnormalities",
"criterion": "echocardiogram",
"requirement": {
"requirement_type": "abnormalities",
"expected_value": "clinically significant"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "echocardiogram with clinically significant abnormalities",
"criterion": "echocardiogram",
"requirement": {
"requirement_type": "abnormalities",
"expected_value": "clinically significant"
}
}
]
}
},
{
"identified_line": {
"line": "* For Dose Escalation (Part A): Have central nervous system malignancy or metastasis",
"criterions": [
{
"exact_snippets": "central nervous system malignancy",
"criterion": "central nervous system malignancy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "metastasis",
"criterion": "metastasis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "central nervous system malignancy",
"criterion": "central nervous system malignancy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "metastasis",
"criterion": "metastasis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* For Dose Confirmation (Part B): Have symptomatic central nervous system malignancy or metastasis",
"criterions": [
{
"exact_snippets": "Have symptomatic central nervous system malignancy",
"criterion": "central nervous system malignancy",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
},
{
"exact_snippets": "metastasis",
"criterion": "metastasis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Have symptomatic central nervous system malignancy",
"criterion": "central nervous system malignancy",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
},
{
"exact_snippets": "metastasis",
"criterion": "metastasis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Have an acute leukemia",
"criterions": [
{
"exact_snippets": "Have an acute leukemia",
"criterion": "acute leukemia",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Have an acute leukemia",
"criterion": "acute leukemia",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and stopped all therapy for that disease for a minimum of 3 years",
"criterions": [
{
"exact_snippets": "Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix)",
"criterion": "history of other cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "unless in complete remission",
"criterion": "complete remission of other cancer",
"requirement": {
"requirement_type": "status",
"expected_value": true
}
},
{
"exact_snippets": "stopped all therapy for that disease for a minimum of 3 years",
"criterion": "therapy cessation for other cancer",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"condition": {
"and_criteria": [
{
"exact_snippets": "Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix)",
"criterion": "history of other cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"not_criteria": {
"exact_snippets": "unless in complete remission",
"criterion": "complete remission of other cancer",
"requirement": {
"requirement_type": "status",
"expected_value": true
}
}
},
{
"not_criteria": {
"exact_snippets": "stopped all therapy for that disease for a minimum of 3 years",
"criterion": "therapy cessation for other cancer",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "years"
}
}
}
}
]
},
"then_criteria": null,
"else_criteria": null
}
},
{
"identified_line": {
"line": "* Have received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug",
"criterions": [
{
"exact_snippets": "received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug",
"criterion": "stem-cell transplant",
"requirement": {
"requirement_type": "type",
"expected_value": [
"autologous",
"allogeneic"
]
}
},
{
"exact_snippets": "received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug",
"criterion": "stem-cell transplant",
"requirement": {
"requirement_type": "time since transplant",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug",
"criterion": "stem-cell transplant",
"requirement": {
"requirement_type": "type",
"expected_value": [
"autologous",
"allogeneic"
]
}
},
{
"exact_snippets": "received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug",
"criterion": "stem-cell transplant",
"requirement": {
"requirement_type": "time since transplant",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "days"
}
}
}
]
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* For Dose Escalation (Part A): cancer, either a solid tumor or a lymphoma",
"criterions": [
{
"exact_snippets": "cancer, either a solid tumor or a lymphoma",
"criterion": "cancer type",
"requirement": {
"requirement_type": "type",
"expected_value": [
"solid tumor",
"lymphoma"
]
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "cancer, either a solid tumor or a lymphoma",
"criterion": "cancer type",
"requirement": {
"requirement_type": "type",
"expected_value": "solid tumor"
}
},
{
"exact_snippets": "cancer, either a solid tumor or a lymphoma",
"criterion": "cancer type",
"requirement": {
"requirement_type": "type",
"expected_value": "lymphoma"
}
}
]
}
},
{
"identified_line": {
"line": "* For Dose Confirmation (Part B): cancer, either a solid tumor or a lymphoma",
"criterions": [
{
"exact_snippets": "cancer, either a solid tumor or a lymphoma",
"criterion": "cancer type",
"requirement": {
"requirement_type": "type",
"expected_value": [
"solid tumor",
"lymphoma"
]
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "cancer, either a solid tumor or a lymphoma",
"criterion": "cancer type",
"requirement": {
"requirement_type": "type",
"expected_value": "solid tumor"
}
},
{
"exact_snippets": "cancer, either a solid tumor or a lymphoma",
"criterion": "cancer type",
"requirement": {
"requirement_type": "type",
"expected_value": "lymphoma"
}
}
]
}
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}